ProBio
ProBio, a U.S. subsidiary of GenScript Biotech Corp., has end-to-end capabilities for biologics discovery & development. With facilities in the U.S., Netherlands, South Korea, and China, ProBIo has enabled its global partners to obtain more than 90 IND approvals since 2017.
More recently, ProBio has committed to internally develop antibody-based therapeutics available for out-licensing, highlighted by the T cell engager candidates derived from our unique CD3 VHH platform.
Towards the mission of “Innovation through Collaboration,” ProBio is committed to helping partners accelerate the development & commercialization of biologics in order to shape a healthier future.
